Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial.

Ariotti, Sara; van Leeuwen, Maarten; Brugaletta, Salvatore; Leonardi, Sergio; Akkerhuis, Kristiaan Martijn; Rexhaj, Emrush; Janssens, Gladys; Ortega-Paz, Luis; Rizzotti, Diego; van den Berge, Jan C; Heg, Dierik Hans; Francolini, Gloria; Windecker, Stephan; Valgimigli, Marco (2017). Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. American Heart Journal, 189, pp. 128-136. Elsevier 10.1016/j.ahj.2017.03.017

	Text 1-s2.0-S0002870317301102-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (879kB)
Preview	Text Ariotti AmHeartJ 2017_postprint.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview

BACKGROUND

Among the 3 approved oral P2Y12 inhibitors for the treatment for patients with acute coronary syndrome (ACS), ticagrelor, but not prasugrel or clopidogrel, has been associated with off-target properties, such as improved endothelial-dependent vasomotion and increased adenosine plasma levels.

METHODS

The HI-TECH study (NCT02587260) is a multinational, randomized, open-label, crossover study with a Latin squares design, conducted at 5 European sites, in which patients free from recurrent ischemic or bleeding events ≥30 days after a qualifying ACS were allocated to sequentially receive a 30 ± 5-day treatment with prasugrel, clopidogrel, and ticagrelor in random order. The primary objective was to evaluate whether ticagrelor, at treatment steady state (ie, after 30 ± 5 days of drug administration), as compared with both clopidogrel and prasugrel, is associated with an improved endothelial function, assessed with peripheral arterial tonometry. Thirty-six patients undergoing evaluable endothelial function assessment for each of the assigned P2Y12 inhibitor were needed to provide 90% power to detect a 10% relative change of the reactive hyperemia index in the ticagrelor group.

CONCLUSION

The HI-TECH study is the first randomized, crossover study aiming to ascertain whether ticagrelor, when administered at approved regimen in post-ACS patients, improves endothelial function as compared with both clopidogrel and prasugrel.

Interest & Impact

Downloads

190 since deposited on 12 Feb 2018
11 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item